Unanswered Questions In Psma-Targeted Radionuclide Therapy

Unanswered questions in PSMA-targeted radionuclide therapy

Dr. Tagawa on Remaining Questions With PSMA-Targeted Radionuclide Therapy in mCRPC

Dr. Tagawa on BRCA2 in Patients with Prostate Cancer Receiving PSMA-Targeted Radionuclide Therapy

PSMA-Targeted Therapy in Prostate Cancer

Cleveland Clinic

Advances in PSMA-targeted therapy for prostate cancer

Unanswered questions for the use of PSMA PET in the staging of prostate cancer

Just the Beginning: What's Next for Radiotheranostics in Prostate Cancer?

Grand Rounds in Urology

PSMA targeted CAR-T therapy for prostate cancer

Promising Agents for the Treatment of Prostate Cancer

177Lu-PSMA-617 radionuclide therapy in mCRPC

PSMA Targeting for Treatment of Advanced Prostate Cancer - 2021 Prostate Cancer Patient Conference

University of California Television (UCTV)

Dr. Tagawa Discusses Agents Targeted Against PSMA

Targeted Oncology

PSMA Targeted Therapies and the Role of the Urologist

Grand Rounds in Urology

Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer

PCa Commentary May 2021 - PSMA Targeted RadioIigand Therapy for Metastatic Prostate Cancer

Grand Rounds in Urology

Michael Morris, MD Discusses the Future of PSMA-Targeted Therapies in APC - Part 1

PSMA: Current State of the Art and Future Vision

Grand Rounds in Urology

ARROW: PSMA-targeted radioligand therapy plus enzalutamide in mCRPC

Dr. Morris of Impact of PSMA-Targeted Imaging on Clinical Management of Prostate Cancer

PSMA - Targeted T Cells for the Treatment of Prostate Cancer